Livewire Ergogenics
LiveWire Ergogenics, Inc., engages in the development and marketing of handcrafted cannabis-based and hemp-derived products for medical and recreational use in the United States. It is also involved in developing and licensing cannabinoid-based specialty products and services under the SOL VIDA Wellness and Estrella Weedery brand names. LiveWire Ergogenics, Inc. is based in Anaheim, California.
Livewire Ergogenics (LVVV) - Net Assets
Latest net assets as of September 2025: $-599.14K USD
Based on the latest financial reports, Livewire Ergogenics (LVVV) has net assets worth $-599.14K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.56 Million) and total liabilities ($4.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-599.14K |
| % of Total Assets | -16.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 285.15 |
Livewire Ergogenics - Net Assets Trend (2008–2024)
This chart illustrates how Livewire Ergogenics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Livewire Ergogenics (2008–2024)
The table below shows the annual net assets of Livewire Ergogenics from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.26 Million | +4.78% |
| 2023-12-31 | $3.11 Million | +53.46% |
| 2022-12-31 | $2.03 Million | +122.45% |
| 2021-12-31 | $912.13K | +184.64% |
| 2020-12-31 | $-1.08 Million | -591.17% |
| 2019-12-31 | $219.41K | +213.27% |
| 2018-12-31 | $-193.70K | +81.00% |
| 2017-12-31 | $-1.02 Million | -9.18% |
| 2016-12-31 | $-933.97K | -9.15% |
| 2015-12-31 | $-855.69K | -25.11% |
| 2014-12-31 | $-683.93K | +10.65% |
| 2013-12-31 | $-765.48K | +14.09% |
| 2012-12-31 | $-891.03K | -13.82% |
| 2011-12-31 | $-782.85K | -1146.91% |
| 2008-12-31 | $-62.78K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Livewire Ergogenics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2643245600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $190.40K | 5.87% |
| Other Comprehensive Income | $428.20K | 13.21% |
| Other Components | $29.21 Million | 900.83% |
| Total Equity | $3.24 Million | 100.00% |
Livewire Ergogenics Competitors by Market Cap
The table below lists competitors of Livewire Ergogenics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Generation Consumer Group Inc
PINK:NGCG
|
$3.62 |
|
Yippy Inc.
PINK:YIPI
|
$3.65 |
|
Itonis Inc
PINK:ITNS
|
$3.69 |
|
Hop-On Inc
PINK:HPNN
|
$3.71 |
|
Zenovia Digital Exchange Corporation
PINK:ZDEC
|
$3.61 |
|
Optigenex Inc
PINK:OPGX
|
$2.97 |
|
Quantum Metal Exchange Inc
PINK:QMEI
|
$2.97 |
|
PMV Consumer Acquisition Corp
PINK:PMVCW
|
$2.97 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Livewire Ergogenics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,113,731 to 3,242,456, a change of 128,725 (4.1%).
- Net income of 78,725 contributed positively to equity growth.
- Other factors increased equity by 50,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $78.72K | +2.43% |
| Other Changes | $50.00K | +1.54% |
| Total Change | $- | 4.13% |
Book Value vs Market Value Analysis
This analysis compares Livewire Ergogenics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.23x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.03x to 0.23x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $0.02 | $0.00 | x |
| 2008-12-31 | $-0.01 | $0.00 | x |
| 2009-12-31 | $0.00 | $0.00 | x |
| 2011-12-31 | $-0.01 | $0.00 | x |
| 2012-12-31 | $-0.01 | $0.00 | x |
| 2013-12-31 | $-0.01 | $0.00 | x |
| 2014-12-31 | $-0.01 | $0.00 | x |
| 2015-12-31 | $0.00 | $0.00 | x |
| 2016-12-31 | $0.00 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $0.00 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $0.00 | $0.00 | x |
| 2024-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Livewire Ergogenics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.89%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 2.46x
- Recent ROE (2.43%) is above the historical average (-55.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -162.27% | 0.00% | 0.00x | 1.00x | $-162.03K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-150.56K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.72K |
| 2011 | 0.00% | -30.16% | 3.78x | 0.00x | $-43.07K |
| 2012 | 0.00% | -1150.41% | 2.15x | 0.00x | $-1.61 Million |
| 2013 | 0.00% | -866.12% | 2.32x | 0.00x | $-1.19 Million |
| 2014 | 0.00% | -1750.94% | 0.77x | 0.00x | $-4.12 Million |
| 2015 | 0.00% | -1085.75% | 0.28x | 0.00x | $-404.43K |
| 2016 | 0.00% | -863.01% | 0.06x | 0.00x | $15.11K |
| 2017 | 0.00% | -5871.41% | 0.18x | 0.00x | $-1.10 Million |
| 2018 | 0.00% | -32465.20% | 0.02x | 0.00x | $-11.57 Million |
| 2019 | -474.92% | -515.93% | 0.10x | 8.89x | $-1.81 Million |
| 2020 | 0.00% | -275.88% | 0.20x | 0.00x | $-1.49 Million |
| 2021 | -376.26% | -403.20% | 0.19x | 4.96x | $-3.52 Million |
| 2022 | 33.72% | 35.30% | 0.31x | 3.09x | $481.22K |
| 2023 | 29.60% | 56.40% | 0.21x | 2.48x | $610.20K |
| 2024 | 2.43% | 25.89% | 0.04x | 2.46x | $-245.52K |
Industry Comparison
This section compares Livewire Ergogenics's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Livewire Ergogenics (LVVV) | $-599.14K | -162.27% | N/A | $3.62 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |